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ORIGINAL ARTICLE
Tumour-suppression function of KLF12 through regulation of
anoikis
N Godin-Heymann1, S Brabetz1, MM Murillo1,2, M Saponaro3, CR Santos4, A Lobley5, P East5, P Chakravarty5, N Matthews6, G Kelly5,
S Jordan1, E Castellano1,7 and J Downward1,2
Suppression of detachment-induced cell death, known as anoikis, is an essential step for cancer metastasis to occur. We report here
that expression of KLF12, a member of the Kruppel-like family of transcription factors, is downregulated in lung cancer cell lines that
have been selected to grow in the absence of cell adhesion. Knockdown of KLF12 in parental cells results in decreased apoptosis
following cell detachment from matrix. KLF12 regulates anoikis by promoting the cell cycle transition through S phase and
therefore cell proliferation. Reduced expression levels of KLF12 results in increased ability of lung cancer cells to form tumours
in vivo and is associated with poorer survival in lung cancer patients. We therefore identify KLF12 as a novel metastasis-suppressor
gene whose loss of function is associated with anoikis resistance through control of the cell cycle.
Oncogene advance online publication, 12 October 2015; doi:10.1038/onc.2015.394
INTRODUCTION
Metastasis is a multi-step process involving tumour cells leaving
their site of origin, spreading via blood or lymph vessels and
forming new tumours at distant sites. Detachment-induced cell
death is an early step in preventing metastasis. When an
untransformed cell detaches from its surrounding matrix or loses
interaction with its neighbouring cells, it undergoes a particular
type of apoptosis known as anoikis.1 Tumour cells that have the
capacity to form metastasis have developed mechanisms to block
anoikis. Improving our understanding of anoikis resistance could
lead to the identiﬁcation of novel potential therapeutic targets.
The effect of the extracellular matrix (ECM) on cells is mainly
mediated by integrins, a family of transmembrane receptors that
bind to the ECM and transduce intracellular signalling pathways.
Upon integrin-mediated adhesion, both FAK and SRC are activated
and they in turn activate various pathways such as phosphatidy-
linositol 3′-kinase/AKT, RAS/RAF/MEK/extracellular signal–regu-
lated kinase (ERK) and nuclear factor-κB, resulting in overall
survival signals.1,2 However, when the integrin signal is lost due to
cell detachment, these survival pathways are no longer dominant
and anoikis occurs. Metastatic cells have developed various
mechanisms to overcome anoikis, including epithelial-to-
mesenchymal transition, changes in integrin repertoire, integrin
internalization, constitutive activation of pro-survival signals such
as autocrine secretion of growth factors or receptor tyrosine
kinase overexpression, oxidative stress, autophagy or entosis.3,4
Apoptosis has been closely linked to the cell cycle as various
proteins are master regulators of both processes. Most promi-
nently, p53 not only regulates the G1 and G2/M phases of the cell
cycle, the spindle checkpoint and centrosome duplication but is
also a major trigger of apoptosis.5 Other regulators that both
stimulate proliferation as well as inducing apoptosis include the
Myc-Max transcription factor complex and E2F1.5 Cyclin-
dependent kinase 1 (CDK1), Cyclin A/CDK2 and cylcin D are
required for cell cycle progression and have been shown to be
essential for inducing apoptosis in some systems.5–8
More speciﬁcally, anoikis sensitivity is associated with cell cycle
regulation. Invasive and motile mesenchymal cells can survive
without ECM interactions and become arrested at the G1 stage of
cell cycle.9,10 Similarly, a population of keratinocytes that survive in
suspension undergo G0/G1 arrest,11 breast epithelial cells over-
expressing galectin-3 are resistant to anoikis in a manner
dependent on their arrest in G112 and mammary epithelial cells
can acquire anoikis resistance following a complete withdrawal
from the cell cycle.13 It has been proposed that late G1 arrest is an
anoikis-insensitive point.12 Brugge and colleagues have shown
that MCF10A cells arrested in G1 or early S phase provide
resistance to anoikis by suppressing BIM expression in a
posttranscriptionally dependent manner.14
The Kruppel-like family (KLF) of transcription factors regulate
multiple processes, such as proliferation, differentiation, migration
and pluripotency.15 Moreover, KLF17 has been shown to be a
repressor of metastasis.16 KLFs can activate and repress genes that
participate in cell cycle regulation. They can be deregulated in
multiple cancers either by loss of heterozygosity, somatic mutations
or transcriptional silencing by promoter methylation.17
KLF12 was initially identiﬁed as a repressor for the transcription
factor AP-2α.18 Ampliﬁcation of the chromosomal region 13q21-
13q22 harbouring KLF12 occurs in salivary gland tumours19 and
poorly differentiated gastric cancers have increased expression of
KLF12 that correlate with tumour size,20 suggesting a possible
oncogenic role. However, the same chromosomal region houses a
putative susceptibility gene in breast, prostrate and pancreatic
cancer and is the site of somatic deletions in different malignant
tumours.21–24
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In order to identify novel regulators of anoikis, we generated
three human lung cancer sublines that were able to survive and
proliferate in suspension. Microarray analysis of these suspension
sublines relative to their parental cell lines showed that all three
had decreased expression of KLF12. Functional analysis showed
that knockdown of KLF12 in the parental cells could supress
anoikis by slowing down S phase. Tail-vein assays conﬁrmed the
role of KLF12 as a suppressor of metastatic colony formation and
higher expression levels of KLF12 correlate with increased survival
of lung cancer patients in clinical data sets.
RESULTS
Characterizing anoikis-resistant cancer sublines
In order to further our understanding of anoikis, we generated
three anoikis-resistant human lung cancer sublines derived from
the well-characterized NCI-60 adherent cell lines A549, H23 and
H460. These sublines were selected by initially growing the cells to
overconﬂuency, collecting the ﬂoating cells and growing these in
adherent conditions. This cycle was repeated 3–4 times, after
which the ﬂoating cells were selected for growth in suspension on
polyHEMA-coated dishes to prevent the cells from adhering. Dead
and dying cells were eliminated by growing the cells on plastic
every few passages. The three suspension-derived cell lines
differed in their macroscopic phenotype when grown on
polyHEMA-coated plates: H460 grew as single cells or pairs of
cells and A549 formed small clumps, whereas H23 grew in large
clumps (Figure 1a).
Assessment of caspase activity of all three suspension-derived
(SUS) cells grown on polyHEMA was signiﬁcantly lower compared
with parental (PAR) cells grown on polyHEMA, showing an
increased resistance to anoikis under these conditions
(Supplementary Figure S1A). As the A549 cell line had an
intermediate phenotype when grown in suspension, further
characterization was performed on this cell line. Cell cycle
proﬁling conﬁrmed that A549 SUS cells were more resistant to
anoikis than the A549 PAR with a sub-G1 population ﬁvefold lower
(Figure 1b). This was further validated by lower levels of cleaved
poly ADP-ribose polymerase in A549 SUS relative to A549 PAR
when grown in suspension (Figure 1c). To assess whether this
increased resistance is speciﬁc to anoikis or a general resistance to
apoptosis, A549 PAR and SUS cells were treated with increasing
doses of doxorubicin (Figure 1d). Both cell lines had a similar
sensitivity to the drug, conﬁrming that the SUS cells were selected
to be speciﬁcally resistant to anoikis rather than more broadly to
apoptosis.
As it has been well documented that overcoming metabolic
stress can have an important role in anoikis resistance,25 we
enquired whether there are any metabolic differences between
the parental and suspension cell sublines that could explain how
these sublines have acquired resistance. When comparing the
basal oxygen consumption rate (OCR) of PAR and SUS cells, no
differences could be detected for A549 and H460 cells, whereas a
drastic reduction in basal OCR was observed in H23 SUS cells
(Supplementary Figure S1B). We split the basal OCR into
mitochondrial ATP production, mitochondrial proton leak and
residual oxygen consumption by a sequential treatment with
oligomycin, antimycin A and rotenone. Thus the loss of basal OCR
in H23 SUS could be pinpointed to a drop in mitochondrial ATP
production and proton leak while the residual oxygen consump-
tion remained unchanged (Supplementary Figure S1C). No
differences, however, were observed in the basal extracellular
acidiﬁcation rate (data not shown). As previous research has
already linked a reduced respiratory chain activity to anoikis
resistance, this observation might have a central role in the anoikis
resistance of H23 SUS cells.26
In order to further characterize the PAR and SUS cell lines, we
tested the activity of core adhesion and anoikis pathways in all
three cell models growing on plastic and polyHEMA (Figure 1e).
This analysis showed a heterogeneous result. All three cell lines
adapted differently to the anchorage-independent growth condi-
tion. The A549 SUS cells show elevated p-Erk levels and lower
levels of the proapoptotic Bim protein. This mechanism of anoikis
resistance has already been characterized, because activated
Erk1/2 phosphorylates BIM and this phosphorylation targets Bim
for ubiquitination and proteasomal degradation.27 As well as their
previously observed speciﬁc metabolic phenotype, H23 SUS cells
are characterized by a high p-Src level that also has been
correlated to anoikis resistance in lung adenocarcinoma cells.28
H460 SUS cells show slightly higher p-Akt levels, a commonly
activated pathway in anoikis resistance.2 All three cell lines have
reduced levels of phospho-FAK when grown on polyHEMA relative
to when they are grown on plastic. As they are not attached to any
ECM when grown on polyHEMA, one would expect reduced
signalling from FAK in those conditions.
KLF12 is downregulated in all three SUS-derived cell lines
Although differences have been observed in metabolism and
signalling in some of the SUS-derived cell lines relative to their
PAR cells, no single underlying mechanism of anoikis resistance
was identiﬁed across all three cell lines. In order to uncover such a
mechanism of resistance, a gene expression microarray analysis
was performed on A549, H23 and H460 PAR cells grown on plastic
and SUS cells grown either on plastic or polyHEMA.
The gene with the largest differential expression in all three cell
lines was KLF12 (Figure 2a), with at least twofold difference in
expression in each of the cell lines between the PAR cells and the
SUS cell lines grown on plastic.
Quantitative PCR (Q-PCR) analysis conﬁrmed that KLF12 mRNA
levels were decreased in the SUS cells relative to the PAR cells
between 3- and 30-fold depending on the cell lines, irrespective of
whether they were grown in adherent conditions on plastic or in
suspension on polyHEMA (Figure 2b). Thus the selection for
decreased levels of KLF12 mRNA is long term, as growth of the
SUS cells on plastic for several passages did not revert KLF12 levels
to those of the PAR cells. To conﬁrm that the differential KLF12
mRNA levels were reﬂected at the protein level, an immunoblot
was performed in all the cell lines (Figure 2c). As the speciﬁcity of
the antibody had previously not been validated, it was conﬁrmed
by short hairpin RNA (shRNA)-mediated knockdown and also
overexpression of a Flag-KLF12 protein (Figure 2c).
KLF12 regulates anoikis
To assess whether KLF12 expression levels correlates with a
functional effect on anoikis, an shRNA hairpin was used to knock
down its expression in the three lung cancer cell lines used to
generate anoikis-resistant cell lines (A549, H23, H460) as well as
the additional lung cancer cell line HOP62 that had higher levels
of KLF12 expression. KLF12 knockdown was efﬁcient in all four
parental cell lines (Figure 3a, bottom panels) and this correlated
with a twofold to fourfold increase in viability of the cells on
polyHEMA relative to a scrambled control (Figure 3a, top panels).
Moreover, the apoptotic population of A549 PAR cells grown on
polyHEMA was signiﬁcantly reduced in cells in which KLF12 was
knocked down by shRNA (Figure 3b). A similar effect was seen
with alternative knockdown approaches, using either a pool of
small interfering RNA (siRNA) oligos against KLF12 (Supplementary
Figure S2A) or an siRNA oligo against the 3′ untranslated region of
KLF12 (Supplementary Figure S2B), indicating that the observed
phenotype was not due to an off-target effect. In all cases, the
apoptotic population was signiﬁcantly reduced upon KLF12
knockdown when the cells were grown on polyHEMA, conﬁrming
a role of KLF12 in anoikis regulation.
KLF12 loss suppresses anoikis
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Figure 1. Characterization of the suspension-derived sublines. (a) Light microscopy images (×10) of A549, H23 and H460 SUS cell lines growing in
suspension (on polyHEMA) for at least 48 h. (b) A549 SUS cells have reduced sub-G1 population relative to A549 PAR cells when grown on
polyHEMA. DNA content assessed by ﬂuorescence-activated cell sorting. The percentage of the sub-G1 population is labelled (left). Histogram
showing an average sub-G1 apoptotic population (n= 3) (right). Following a one-way analysis of variance, the P-values were determined to be
0.00003 comparing PAR plastic and PAR pHEMA and 0.000124 comparing PAR pHEMA and SUS pHEMA, n= 3. (c) Apoptosis induction assessed
by poly ADP-ribose polymerase cleavage in A549 PAR compared with attenuated response in SUS cells grown on polyHEMA. (d) A549 PAR and
SUS cell lines were treated in triplicates with serial dilutions of doxorubicin in adherent conditions. (e) Cell signalling proﬁling of parental and
suspension A549, H23 and H460. Cells were cultured for 48 h on plastic or on polyHEMA. Cell extracts were subjected to immunoblotting with
p-FAK(Y397), p-Src (Y416), p-Erk (T202/Y204), p-Akt (S473), Bim, total FAK, Src, Erk, Akt and β-actin antibodies.
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KLF12 has a role in cell cycle regulation
KLF12 is a member of the KLF of transcription factor and has
previously been described as a repressor of the transcription
factor AP-2α.18 AP-2αmRNA was not differentially expressed in the
PAR compared with the SUS cell lines across all three cell lines
either in the microarray data or by Q-PCR analysis (Supplementary
Figure S3A and data not shown), suggesting an alternative
mechanism for the effect of KLF12 on anoikis.
In order to provide an unbiased analysis of genes regulated by
KLF12, the KLF12 gene was silenced in PAR A549 by either siRNA
or shRNA, and an RNAseq was performed in triplicate. Interest-
ingly, there were signiﬁcantly more genes differentially expressed
following siRNA-mediated knockdown of KLF12 relative to shRNA-
mediated knockdown, namely 5039 versus 2142. This could be
due to the siRNA pool having increased off-target effects relative
to the shRNA hairpin or to a more efﬁcient level of KLF12 silencing
by siRNA. A selection of genes that were shown to be upregulated
or downregulated in KLF12 siRNA by RNAseq were validated by
Q-PCR giving conﬁdence in the results (Supplementary Figures
S3B and C).
As integrin signalling has a key role in anoikis regulation, we
wanted to establish whether KLF12 was involved in that pathway.
Indeed, we identiﬁed a signiﬁcant integrin signature using
DAVID29 within our differentially expressed genes following KLF12
knockdown by siRNA; however, it was not statistically signiﬁcant
following KLF12 knockdown by shRNA (Supplementary Figure S3D).
To increase the conﬁdence that we selected targets of KLF12,
we analysed the genes that overlapped in the siRNA- and shRNA-
mediated knockdown RNAseq in the same direction (Figure 4a).
Gene ontology analysis using Metacore’s Pathway tool identiﬁed
cell cycle as the most signiﬁcant process in all of the overlapping
genes following RNA interference, as well as in those genes
that were upregulated after siRNA and shRNA knockdown of
KLF12 (Figure 4b). Q-PCR analysis conﬁrmed the differential
expression of these cell cycle genes following KLF12 knockdown
(Supplementary Figure S4A). Indeed, knockdown of KLF12 in A549
increased the percentage of bromodeoxyuridine (BrdU)-positive
cells undergoing S phase, thereby conﬁrming a role of KLF12 in
cell cycle regulation (Figure 4c).
An increase of BrdU-positive population could be due to either
an increase in cell cycle, whereby more cells are cycling and
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therefore in S phase, or a slowing down/blockage of cell cycle in S
phase, resulting in an accumulation of cells in mid–late S phase. To
differentiate between these two opposing possibilities, a BrdU
pulse chase was performed and the length of the cell cycle was
determined in cells with KLF12 knockdown relative to scrambled
control. Whereas the initial steps of cell cycle showed no
difference between siKLF12 and scramble samples, a delay
occurred 4 h after the BrdU pulse, with 69% BrdU-positive cells
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in mid–late S phase in scramble samples compared with 81% of
cells that had decreased levels of KLF12 (Figure 4d). This delay in
S-phase exit was short-lived as 6 h after the pulse the two samples
showed similar BrdU proﬁles. To investigate whether this effect
was speciﬁc to A549 or more general, a pulse chase was also
performed in H460 cells with KLF12 knocked down or scramble
control. As with A549, KLF12 silencing in H460 showed a delay in
mid–late S phase (Supplementary Figure S4B). Thus KLF12
knockdown results in a small but consistent delay to exit S phase.
To assess whether the effect of KLF12 observed on cell cycle
proﬁle is translated into an effect on cell growth, IncuCyte live cell
imaging was performed on A549 and H460 cells with KLF12
silencing. Measurements taken every 3 min showed a clear
decrease in relative growth of cells that had knocked down
KLF12 compared with scrambled control (Figure 5a). Moreover,
population doublings were almost halved in A549, H460 and
HOP62 cells with KLF12 knockdown relative to scrambled control
(Figure 5b).
We wanted to determine whether the cell cycle role of KLF12
was linked to its role in anoikis. To this effect, we used low doses
of the S-phase inhibitor aphidicolin to slow down the cell cycle in
an attempt to mimic the effect of KLF12 knockdown in A549
(Supplementary Figure S5). Aphidicolin treatment had little effect
on Annexin V proﬁling when grown on plastic. However, it was
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able to signiﬁcantly reduce the apoptotic population of cells
grown on polyHEMA compared with those treated with a dimethyl
sulphoxide control (Figure 5c). Thus we suggest that KLF12
promotes anoikis by regulating the cell cycle.
KLF12 inﬂuences anoikis resistance in vivo
To assess whether KLF12 has a tumour-suppressor role in vivo, the
gene was knocked down in HOP62, the cell line studied which
expresses the highest levels of KLF12 and is the most sensitive to
KLF12 knockdown in vitro. Luciferase-expressing HOP62 cells were
infected with either control scrambled shRNA or shRNA against
KLF12 and were injected into the tail vein of immunodeﬁcient
mice. Fifteen weeks after injection, the HOP62 cells that had
decreased KLF12 expression could be visualized with increased
signal relative to the control cells (Figure 6a).
An experimental metastasis assay was also performed with
luciferase-expressing A549 cells infected with scrambled control or
shRNA against KLF12. As the majority of cells are cleared soon after
injection, the luciferase activity was monitored at 5 h, 1day, 2 days
and 3 days postinjection. The signal of all samples were normalized
at 5 h after injection, and within 2 days a statistical difference was
noticed with the KLF12-knockdown cells having a higher signal in
the lungs compared with the scrambled control (Figure 6b). This
difference was further increased at 3 days postinjection. The
scrambled control-infected cells had progressively lower signals as
the days progressed, suggesting that the cells underwent anoikis.
On the other hand, the cells with KLF12 knockdown seemed to
either remain at a similar level to the initial luciferase signal or have
a decreased signal, suggesting that whereas some cells were dying,
others could survive albeit not proliferate signiﬁcantly. This ﬁts with
the previous data that suggest that KLF12 knockdown can promote
anoikis resistance but in parallel slows down the cell cycle. Thus
KLF12 expression can affect both short-term and long-term survival
in a tail-vein assay.
To assess the role KLF12 might have in a clinical setting, a
publicly available microarray database that is correlated with lung
cancer patient survival was analysed using a cutoff of 37 tumour
samples based on KLF12 expression levels.30 Patients with higher
KLF12 mRNA levels had increased overall survival relative to those
with lower KLF12 levels (Figure 6c). Indeed, at a survival
probability of 0.5, patients with higher KLF12 expression levels
survived a further 24 months compared with those with lower
expression levels. Thus KLF12 could act as a potential tumour
suppressor in lung cancer.
DISCUSSION
Suppression of anoikis is an early step in the cascade leading to
metastasis. The regulation of this specialized form of apoptosis is
complex and still only partly understood. In the present study, we
identify KLF12 as a novel candidate tumour-suppressor gene
involved in detachment-induced cell death. KLF12 promotes the
G1/S transition of the cell cycle and by doing so makes the cell
more susceptible to undergo anoikis. Knocking down KLF12
results in increased survival of lung cancer cells growing in
suspension as well as increased tumour formation in a mouse
experimental metastasis model. Moreover, low KLF12 expression
levels correlate with reduced survival in lung cancer patients.
Although tumour suppressors have traditionally been thought of
as inhibitors of the cell cycle, it has previously been demonstrated
that blocking the cell cycle could confer anoikis resistance in the
MCF10A model,14 and we conﬁrm here that aphidicolin treatment
could mimic KLF12 knockdown effect on anoikis resistance.
RNAseq analysis of A549 cells showed that a signiﬁcant number
of genes were differentially expressed following KLF12 knock-
down. Although KLF12 had previously been described as a
transcriptional repressor, our analysis showed genes that were
both upregulated and downregulated. This could be due to an
indirect effect whereby KLF12 represses another transcriptional
repressor or to the fact that KLF12 could repress as well as
transactivate its targets. Indeed, whereas KLF8 was also identiﬁed
as being a transcriptional repressor by recruiting CtBP, it has been
shown to transactivate certain genes as well,31–33 raising the
possibility that KLF12 could repress as well as transactivate its
targets. A chromatin immunoprecipitation-seq analysis would tell
us which of those genes are direct as opposed to indirect targets
of KLF12. Unfortunately, we were unable to perform those
experiments owing to the unsuitability of the antibodies currently
available.
KLF12 has previously been reported to have an oncogenic role
in gastric and head and neck cancers,19,20 although other studies
suggest KLF12 might have a tumour-suppressive role. Other KLFs
have been reported to be tumour suppressors or oncogenes, with
their function dependent on tumour types or cancer stage.15 For
example, KLF5 is growth promoting in non-transformed epithelial
cells, while it has growth-inhibitory properties in colon tumour-
derived cells.34 This difference of KLF5 effect was dependent on
whether the cells expressed wild-type or mutant p53 owing to
competition between KLF5 and p53 to bind p21 promoter.15,35
Thus the discrepancy between KLF12 role as an oncogene or a
tumour suppressor is likely to be context dependent.
Mutant Ras is known to have a role in anoikis resistance,10,36–42
and it is worth noting that the cell lines used in these experiments,
A549, H460, H23 and HOP62, all contain a mutant K-Ras gene. It is
as yet unclear whether the Ras mutant status has any effect on
KLF12 and its role in anoikis suppression, but this would be worth
addressing in the future. Interestingly, although prostate cancer is
not commonly associated with Ras mutations, there is also a
correlation between KLF12 expression levels and survival of
prostate cancer patients (Supplementary Figure S6).43 This raises
the possibility that the tumour-suppressive role of KLF12 might be
independent of Ras mutational status and also suggests that
KLF12 might have a broader role in carcinogenesis, not limited to
lung cancer.
For metastasis to occur, cancer cells need not only be resistant
to anoikis but also proliferate at distant sites. As we have seen,
decreased KLF12 expression leads to the former but slows down
proliferation rather than promotes it. We hypothesize that KLF12
downregulation is an early step in metastasis that allows cells to
adapt to anchorage-independent cell growth conditions and gives
them time for further genetic or epigenetic selection to occur. The
diversity in signalling and metabolism the different cell lines have
acquired, such as increased P-Erk in A549, elevated p-Src and
decreased OCR in H23 and higher levels of P-Akt in H460 cells,
might be secondary resistance steps that occur after selection of
decreased KLF12 levels.
We thus propose that anoikis resistance is a multi-step process
and that loss of KLF12 expression occurs at an early stage. This
allows tumour cells to adapt further to anoikis resistance in a
variety of ways, so that the cells can then proliferate at distal sites.
MATERIALS AND METHODS
Cell culture, viability and proliferation assays
The expression of the luciferase enzyme in the cell lines was monitored
using an IVIS Spectrum Pre-Clinical In Vivo Imagine System (Caliper Life
Sciences, Hopkinton, MA, USA). Doxorubicin was purchased from
Calbiochem (Billerica, MA, USA), Aphidicolin and polyHEMA from Sigma
(St Louis, MO, USA) and were used as previously described.44 Viability
assays were performed as previously described.45 Cell growth/conﬂuence
was measured in real time on an Incucyte FLR (Essen Instruments,
Ann Arbor, MI, USA). Proliferation in culture was assayed as previously
described.46
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Cloning, reverse transcriptase Q-PCR and antibodies
KLF12 was PCR ampliﬁed from a human cDNA library introducing
an N-terminal FLAG tag and sequenced. Oligos are described in
Supplementary Table S1a. The luciferase gene was cloned into
BamH1/SalI cloning sites of a pBabe-Blastocidin retroviral expression
vector. Primer details for reverse transcriptase Q-PCR and
antibody details are provided in Supplementary Tables S1d and e,
respectively.
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siRNA transfection and shRNA production and infection
Cells were transfected with siRNAs by reverse transfection using
Dharmafect 1 as per the manufacturer’s methods (Dharmacon, Lafayette,
CO, USA). Retroviral and lentiviral production and infection were
performed as previously described.47 shRNA and siRNA details are in
Supplementary Tables S1b and c, respectively.
Flow cytometry
For cell cycle proﬁling, adherent and suspension cells were collected, ﬁxed
with 70% ethanol and stained with propidium iodide. For BrdU treatment,
cells were treated with 10 μM for 1 h after which the cells were harvested
and ﬁxed as described above. For BrdU pulse-chase assays, cells were
pulsed with 10 μM BrdU for 15min after which they were washed with
phosphate-buffered saline and grown in full serum for the indicated times
prior to harvesting, as described above. For apoptosis analysis, ﬂoating
and adherent cells were harvested, resuspended in Binding Buffer
(BD Biosciences, Franklin Lakes, NJ, USA), stained with Annexin V–
ﬂuorescein isothiocyanate antibody and propidium iodide and analysed
by ﬂow cytometry.
Metabolic assays
O2 consumption were measured using the Seahorse XFe Extracellular Flux
Analyzer (North Billerica, MA, USA) according to the manufacturer’s
standard protocol. For normalization, cells were seeded in parallel in a 96-
well plate, ﬁxed in 70% ethanol and stained with 4,6-diamidino-2-
phenylindole (DAPI; 1 μg/ml DAPI in phosphate-buffered saline) for 1 h.
The cell count was measured by the Acumen eX3 Analyzer (TTP Labtech,
Hertfordshire, UK) by determining the total area of DAPI staining and
dividing it by the area of a single nucleus.
Gene expression analysis
The NimbleGen microarray was performed in triplicates following the
manufacturer’s protocol (Roche, Basel, Switzerland). Four micrograms of
Cy3-labelled double-stranded cDNA was hybridized to a NimbleGen Gene
Expression array. The array data were normalized by Robust Multi-array
Average. Statistical signiﬁcance was assessed by one-way analysis of
variance with a false-discovery rate of 0.05. The analysis was carried out
using Limma from Bioconductor. We selected differential probes using a
0.05 false-discovery rate and a fold difference of at least twofold in each of
the different cell lines.
RNASeq quantitation
Illumina (San Diego, CA, USA) 72 base pair single-ended reads were aligned
to UCSC human genome reference hg19 (40e6 reads/sample)48 using the
Tophat2 algorithm.49 KnownGene annotations from UCSC provided
transcript annotations for the reference genome. Differential expression
levels between cell line and control samples were quantiﬁed for the known
genes using Cuffdiff.50 Gene lists for each sample–control pair comprised
those that were selected from the Cuffdiff results, which were differentially
expressed at a P-valueo0.001. Venn logic was applied to the lists to obtain
those genesets speciﬁc to each sample–control pair.
Experimental metastasis assays
Hop62 and A549 cells expressing stable levels of luciferase were
suspended in phosphate-buffered saline to a concentration of 106 cells/
0.2 ml. A total of 0.2 ml of these solutions was injected into the tail vein of
different groups of Nod/Scid Gamma mice. Bioluminescence emission of
the cells injected was monitored at different time points using an IVIS
Spectrum Pre-Clinical In Vivo Imagine System according to the manufac-
turer’s instructions.
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